

Alicante, 23 of October 2026

COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "Facephi" or "the Company") hereby notifies the following:

The Company hereby informs the market that, in connection with the Other Relevant Information ("OIR") published on 14 May regarding the consultation submitted to the Spanish Institute of Accounting and Auditing ("ICAC") concerning the accounting treatment applied to certain transactions involving Economic Interest Groupings ("AIEs") and the recognition of revenue associated with tax financing structures for R&D activities, the response received from ICAC, while not conclusive, establishes the parameters to be followed in applying the relevant accounting criteria.

The Company's Directors have reassessed the aforementioned criteria and concluded that the individual and consolidated financial statements for the 2025 financial year do not require any amendment to those approved by the General Shareholders' Meeting.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors